Released May 10, 2018, after the close
10-Q filed May 10, 2018, 40 days after period end · 0001564590-18-012939
Q1 2018 · 10-Q
Revenue$1.03M$1.03M −0.1% vs Q1 2017−0.1% vs Q4 2017
Net Income-$14.14M-$14.14M N/M vs Q1 2017N/M vs Q4 2017
EPS Diluted-$0.27-$0.27 N/M vs Q1 2017N/M vs Q4 2017
Operating Income-$14,054,000N/M
Operating Cash Flow-$12,551,000N/M
Free Cash Flowderived-$12,735,000N/M
Margins · derived
Operating margin-1369.8%−398.9 pt vs Q1 2017
Net margin-1377.7%−391.7 pt vs Q1 2017
What the release said
The release
Same quarter
| Metric | Q1 2018 | Q1 2017 | Q1 2016 | Q1 2015 |
|---|---|---|---|---|
| Revenue | $1.03M | $1.03M | $1.32M | — |
| Net Income | -$14.14M | -$10.13M | -$8.38M | -$7.88M |
| EPS Diluted | -$0.27 | -$0.24 | -$0.29 | -$0.38 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR